Background: Various types of radiocontrast media (RCM), which can be substituted for each other, are used in clinical settings. However, data on comparisons of hypersensitivity reactions (HSR) based on types of RCM are lacking.
Introduction
The use of radiocontrast media (RCM) has increased along with the increase in the use of imaging modalities, especially computed tomography (CT). 1 The hypersensitivity reaction (HSR) rate associated with RCM is known to be fairly high; 2, 3 therefore efforts to reduce the HSR rate has been the focus of numerous studies. Non-ionic RCM were introduced to replace ionic RCM, which reduced the HSR rate. 4, 5 Moreover, the HSR rate reduced consderably after high-osmolar RCM were replaced by iso-and low-osmolar types. [6] [7] [8] Further, there have been reports that HSR rates among iso-and low-osmolar RCM were not significantly different. [9] [10] [11] [12] [13] To date, various types of iso-and low-osmolar RCM, which can be easily substituted each other, have been used. However, recent large-scale studies have revealed that adverse drug reaction (ADR) rates differ significantly according to the type of RCM. Gomi et al.
14 compared the incidence of acute ADRs among five low-osmolar RCM including iomeprol, iopamidol, iohexol, iopromide, and ioversol. They discovered that the use of iopamidol, iohexol, and ioversol significantly reduced the incidence of ADRs. Kim et al. 15 reviewed 286,087 cases of low-osmolar RCM use and found that compared to iohexol, iopamidol, and iopromide, iobitridol significantly
Methods

Data collection
We retrospectively reviewed 215,135 incidences of RCM use that occurred at Gangnam Severance Hospital from January 2011 to December 2015. Gangnam Severance Hospital, which is a branch of Severance Hospital, implemented a previously described spontaneous reporting program at Severance Hospital to report ADRs from 2005. 15 ,17 Doctors, nurses, and paramedics have spontaneously reported ADRs using this program. We analyzed HSR events among ADRs in patients in whom RCM were used, by using this internally developed ADR reporting system.
RCM analyzed in this study
The RCM investigated in this study were iohexol (Bonorex® 300, GE Healthcare, Amersham, UK), ioxitalamic acid (Telebrix® 30, Guerbet, Sulzbach, Germany), ioversol (Optiray® 320, Guerbet, Sulzbach, Germany), iobitridol (Xenetix® 300, Guerbet, Sulzbach, Germany), iopromide (Ultravist® 300, Bayer, Leverkusen, Germany), iopamidol (Pamiray® 300, Bracco, Milan, Italy), and iodixanol (Visipaque®, GE Healthcare, Amersham, UK). Among them, ioxitalamic acid is an ionic RCM and iodixanol is a non-ionic iso-osmolar RCM. Except for these two, the others are non-ionic low-osmolar RCM.
Definition of HSR and severity of HSR
HSR was defined as a particular condition causes the immune system to overreact and included all allergic reactions (which is defined as one type of HSR when immune system overreacts to harmless substances) and various non-allergic reactions according to American Academy of Allergy Asthma & Immunology definition. 18 Immediate HSR was defined as a HSR occurring within 1 hour after administration of a RCM.
The HSR severity was classified as follows: mild (itching, urticaria, flushing, nausea, mild vomiting, and/or chills, i.e. symptoms that are self-limited, without evidence of progression), moderate (severe vomiting, systemic urticaria, mild bronchospasm, face and/or larynx angioedema, throat tightness, tachycardia, bradycardia, mild dyspnea, hypoxia, and/or temporary hypotension, i.e. symptoms that are more pronounced and commonly require medical management), and severe (shock, pulmonary edema, prolonged hypoxia, cardiopulmonary arrest, and/or convulsions, i.e. symptoms that are often life-threatening and can result in permanent morbidity or death if not managed appropriately). 19 In addition, we defined anaphylaxis as a serious allergic reaction that is rapid in onset and may cause death , when any one of the following 3 criteria are fulfilled: acute onset of an illness with involvement of the skin, mucosal tissues, or both and other sympotms (respisratory compromise or reduced BP or associated symptoms of end-organ dysfunction); two or more symptoms (involvement of the
Results
Clinical characteristics
During the 5-year study period, 209,027 incidences of RCM use occurred in 97,374 patients. During that period, 108 HSR events occurred in 88 patients (0.05% events). We divided the patients into subjects without and with HSR (n = 97,286 and 88, respectively). Age, sex, and the prevalence of asthma, allergic rhinitis, atopic dermatitis, hypertension, diabetes mellitus, liver disease, and chronic renal disease were not significantly different between the two groups. However, prevalence of urticaria (10.2%) was significantly higher in subjects with HSR than that in subjects without HSR (3.3%, P = 0.003). The prevalence of food allergy (3.4%) and drug allergy (19.3%) was also significantly higher in subjects with HSR than that in subjects without HSR (0.6 and 1.2%), respectively ( Table 1) .
Clinical manifestations of HSR
Among the 108 HSR events, cutaneous symptoms including rash, pruritus, and urticaria were the most frequent manifestations (88.9%). Nausea/vomiting (13.0%), angioedema (5.6%), and dyspnea (3.7%) were also frequently observed. Chest pain, unconsciousness, and shock were rarely observed (0.9%, Table  2 ).
HSR rates according to time
The HSR rates in 2014 and 2015 (0.09% and 0.07%) were significantly higher than those in 2011-2013 (0.03%, P < 0.001). Further, upon categorizing them into 2011-2013 and 2014-2015, the differences were still significant ( Table 3) .
HSR rates according to the type of RCM
The HSR rate for iodixanol (0.16%) was the highest, followed by that for iopamidol (0.08%), iopromide (0.04%), and iobitridol (0.04%). Ioversol (0.02%), ioxitalamic acid (0.01%), and iohexol (0.01%) were associated with relatively low incidences of HSR. The difference in HSR rate was significant among the reduced immediate HSR. Morales-Cabeza et al. 16 showed immediate reaction was significantly lower in iopamidol and ioversol rather than iomeprol. To date, data on the comparison of HSR rates based on the type of RCM are lacking. Therefore, we aimed to compare the HSR rate to facilitate the selection of appropriate and safe RCM in clinical practice.
skin-mucosal tissue, respiratory compromise, reduced BP or associated symptoms, or persistent gastrointestinal symptoms) that occur rapidly after exposure to a likely allergen; reduced BP after exposure to known allergen. 20 
Statistical analysis
We used the Student's t-test with an analysis of variance (ANOVA) and chi-square tests to identify any differences in continuous and categorized variables between groups, respectively. Univariate and multivariate analyses were used to determine significant factors associated with HSR using a logistic regression analysis and generalized estimating equation (GEE) analysis. The Statistical Package for the Social Sciences (SPSS) v18.0 (IBM Corp, Armonk, NY, USA) was used, and a P < 0.05 was considered statistically significant.
Ethics
This study was exempted from requiring an approval by the Institutional Review Board of the Gangnam Severance Hospital, Yonsei University Health System (approval number: 3-2016 -0207) Table 3 and Figure 1 ). The high viscosity is associated with a high laminar flow, which may lead to renal toxicity. 24 However, some researchers have reported opposite findings. 25, 26 Although we assumed that the results obtained in this study are due to the high viscosity of iodixanol, further studies are needed to verify this finding.
Logistic regression analysis of the risk factors for HSR
This study showed that the use of ioxitalmic acid, which is an ionic monomer, is not a high risk factor for HSR. Although various RCM with lower osmolarity and low toxicity have been developed, ioxitalmic acid is still used clinically. The low viscosity of ioxitalmic acid makes it suitable for use in thinner -walled catheters. Furthermore, the relatively low biological tolerability of ionic RCM also contributed to its widespread use. 23 In addition, the highly water-soluble characteristics of ionic RCM are also important factors for its continued used. 27 We suggest that ioxitalmic acid can be used relatively safely for some specific purposes.
We found that age, urticaria, and drug allergy were significant risk factors for HSR. These factors are already well -established risk factors for HSR as previously reported in the literature. 22, 28 However, two previous large-scale studies conducted to compare the incidence of HSR among RCM by Gomi et al. 14 and Kim et al. 15 did not consider these factors. In addition, these studies did not adjust for these factors in their comparisons. Our consideration of these factors with adjustment has contributed to strengthening this present study. For the first time, we have defined the significant difference in the HSR rate among RCM while adjusting for age, urticaria, and drug allergy.
The timing of use was also a significant risk factor for HSR in this study. However, we thought that this factor is not clinically significant, but likely just a confounding factor. The HSR event data were collected using an internally developed ADR reporting system. Following the launch of this reporting system in this institute, allergy specialists, pharmacists, and other drug-related professionals encouraged doctors, nurses, and paramedics to use this system for several years. This increased the ADR reporting rate significantly according to the time. This factor might also be a confounding factor. We adjusted this factor in the multivariate analysis, and the results were not affected by this confounding factor.
This study had some limitations, which are worth mentioning. First, the spontaneous reporting rate was supposed to be low. Compared to previous studies, which reported the incidence of ADR as 0.1-2.5% .
14,29-31 the reported ADR rate in this study (0.03-0.17%) is slightly low. The reported ADR rate in this study might not reflect all the ADRs that occurred because the data were not collected automatically, but were collected by using a spontaneous reporting system. Second, this study was performed in only one institute with selected RCM, which are concordant with only one product. The characteristics of RCM used in this study may be limited to the specific products, and may not apply to all products containing these ingredients. Third, we did not include GEE analysis of severe HSR, separately, as it can cause distorted results. Last, premedication could not be assessed in this study. 
Discussion
We defined the significant risk factors for HSR, based on a retrospective review of 209,027 RCM use events that occurred in one institute. Seven types of RCM were used, and five were classified as low-osmolar RCM, which have been widely used recently. Among the five types of low-osmolar RCM, iopamidol use was a significant risk factor for HSR. Identifying RCM with high and low risks for HSR is very important in a clinic setting because the prevalence of HSR with RCM use is increasing. Furthermore, numerous guidelines and researchers recommend that RCM that have induced HSR in a subject should be replaced with another agent and that premedication will be helpful to reduce risk for recurrence of HSR, but some others showed skeptical results. 19, 21, 22 Until now, no consensus has been reached on the types of RCM that are safer and suitable substitutes for avoiding ADRs. We also cannot firmly recommend which RCM is safer and suitable. But the results of this study which showed that iopamidol has a relatively higher risk associated with its use than that associated with iohexol or ioversol use will be informative when clinicians chose type of RCM. Gomi et al.
14 also showed that the incidence of ADRs with iopamidol use (2.2%) was relatively higher than that with iohexol (2.0%) and ioversol use (1.8%). Kim et al. 15 also showed that incidence of anaphylaxis with iopamidol use (0.023%) was relatively higher than it was with iohexol use (0.018%). These results will be helpful to choose type of ADR in clinical setting.
We discovered that the iso-osmolar RCM, iodixanol, exhibited the highest risk for HSR. The transition from the use of ionic monomers to nonionic monomers (low-osmolar) and then to nonionic dimers (iso-osmolar RCM) was initiated to reduce toxicity. Iodixanol is one of the first-generation non -ionic dimers that are manufactured as isotonic agents useful
Conclusion
This study showed that use of iodixanol (iso-osmolar RCM) is a high risk factor for immediate HSR. Among the low-osmolar RCM, iopamidol use is associated with a significantly higher risk for immediate HSR than iohexol or ioversol use is. Compared to other RCM, ioxitalamic acid (ionic RCM) use is not a high risk factor for immediate HSR. This information may be helpful to clinicians in choosing the most appropriate RCM type.
